tiprankstipranks
Trending News
More News >
Regulus Therapeutics Inc (RGLS)
:RGLS
US Market

Regulus (RGLS) Price & Analysis

Compare
Followers

RGLS Stock Chart & Stats

$8.16
$0.00(0.00%)
--

Regulus News

RGLS FAQ

What was Regulus Therapeutics Inc’s price range in the past 12 months?
Currently, no data Available
What is Regulus Therapeutics Inc’s market cap?
Currently, no data Available
When is Regulus Therapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Regulus Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Regulus Therapeutics Inc overvalued?
According to Wall Street analysts Regulus Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
    Does Regulus Therapeutics Inc pay dividends?
    Regulus Therapeutics Inc does not currently pay dividends.
    What is Regulus Therapeutics Inc’s EPS estimate?
    Regulus Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Regulus Therapeutics Inc have?
    Currently, no data Available
    What happened to Regulus Therapeutics Inc’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Regulus Therapeutics Inc?
    Currently, no hedge funds are holding shares in RGLS
    What is the TipRanks Smart Score and how is it calculated?
    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

      Company Description

      Regulus Therapeutics Inc

      Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. The company operates in the biotechnology sector, primarily working on therapies to address unmet medical needs in various diseases. Regulus's core offerings include a pipeline of microRNA therapeutics aimed at treating conditions like genetic kidney diseases and other serious health issues.

      Ownership Overview

      0.02%99.98%
      Insiders
      0.02%
      Mutual Funds
      ― Other Institutional Investors
      99.98% Public Companies and
      Individual Investors

      Options Prices

      Currently, No data available
      ---
      Popular Stocks